Literature DB >> 31533984

Evaluation of Standard E TB-Feron Enzyme-Linked Immunosorbent Assay for Diagnosis of Latent Tuberculosis Infection in Health Care Workers.

Oh Joo Kweon1, Yong Kwan Lim1, Hye Ryoun Kim1, Tae-Hyoung Kim2, Mi-Kyung Lee3.   

Abstract

The laboratory diagnosis of latent tuberculosis infection (LTBI) is mainly performed with interferon gamma release assays (IGRAs). We compared the performance of a new enzyme-linked immunosorbent assay (ELISA)-based IGRA, the Standard E TB-Feron ELISA (TBF; SD Biosensor, Gyeonggi-do, Republic of Korea), with that of a widely used assay, the QuantiFERON-TB Gold In-Tube assay (QFT-GIT; Qiagen, Hilden, Germany), in a population of 425 health care workers (HCWs). All HCWs were screened by both assays per the manufacturers' protocols and in a cross-manner, where tube sets from one assay were used with the alternative ELISA. The results were compared both qualitatively and quantitatively. TBF and QFT-GIT identified 11.3% (48/425) and 12.9% (55/425) of the positive samples, respectively. TBF demonstrated 81.6% positive and 97.4% negative percent agreement with QFT-GIT, with a Cohen's kappa value of 0.78 (strong agreement). Discordant results were detected in 20 subjects (4.3%): 13 samples (65.0%) were TBF negative and QFT-GIT positive, 6 samples (30.0%) were TBF positive and QFT-GIT negative, and 1 sample provided TBF and QFT-GIT indeterminate/negative results. We observed a statistically significant degree of correlation between the interferon gamma reactivity between the two assays (Spearman's rho [rs ] value = 0.551, P < 0.01) and between standard assays and cross-manner tests (rs value range, 0.449 to 0.816; P < 0.01 for all combinations). Cross-manner tests also revealed that the ELISA kit of TBF provided higher values for the tube containing the tuberculosis (TB) antigen and the negative-control tube than the ELISA of QFT-GIT under the same conditions (P < 0.01), although these differences disappeared when the value for the negative-control tube was subtracted from that for the TB antigen tube. TBF showed a comparable and acceptable clinical performance in detecting LTBI compared to QFT-GIT. TBF represents a useful alternative tool as an ELISA-based IGRA, especially for large-scale screening for LTBI in HCWs.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  QuantiFERON-TB Gold In-Tube ELISA; Standard E TB-Feron ELISA kit; interferon gamma release assay; latent tuberculosis infection

Year:  2019        PMID: 31533984      PMCID: PMC6879280          DOI: 10.1128/JCM.01347-19

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  25 in total

Review 1.  Treatment of Latent Tuberculosis Infection.

Authors:  Connie A Haley
Journal:  Microbiol Spectr       Date:  2017-04

2.  QuantiFERON-TB Gold test in the identification of latent tuberculosis infection in immigrants.

Authors:  Anna C C Carvalho; Maria Chiara Pezzoli; Issa El-Hamad; Patricia Arce; Sara Bigoni; Carmelo Scarcella; Anna Maria Indelicato; Carla Scolari; Giampiero Carosi; Alberto Matteelli
Journal:  J Infect       Date:  2007-04-10       Impact factor: 6.072

3.  Statistics corner: A guide to appropriate use of correlation coefficient in medical research.

Authors:  M M Mukaka
Journal:  Malawi Med J       Date:  2012-09       Impact factor: 0.875

4.  Defective antigen tubes generate false-positive QuantiFERON tuberculosis test results.

Authors:  Marc Roger Couturier; Robbie Myatt; Don Dorn; David T Yang; Nancy Pitstick
Journal:  Clin Infect Dis       Date:  2014-08-08       Impact factor: 9.079

Review 5.  Preventive therapy for latent tuberculosis infection-the promise and the challenges.

Authors:  G J Fox; C C Dobler; B J Marais; J T Denholm
Journal:  Int J Infect Dis       Date:  2016-11-18       Impact factor: 3.623

Review 6.  Latent Mycobacterium tuberculosis Infection and Interferon-Gamma Release Assays.

Authors:  Madhukar Pai; Marcel Behr
Journal:  Microbiol Spectr       Date:  2016-10

7.  Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005.

Authors:  Paul A Jensen; Lauren A Lambert; Michael F Iademarco; Renee Ridzon
Journal:  MMWR Recomm Rep       Date:  2005-12-30

8.  Impact of blood volume, tube shaking, and incubation time on reproducibility of QuantiFERON-TB gold in-tube assay.

Authors:  Rajiv L Gaur; Madhukar Pai; Niaz Banaei
Journal:  J Clin Microbiol       Date:  2013-08-21       Impact factor: 5.948

9.  Interferon-gamma release assays for the tuberculosis serial testing of health care workers: a systematic review.

Authors:  Felix C Ringshausen; Anja Schablon; Albert Nienhaus
Journal:  J Occup Med Toxicol       Date:  2012-06-18       Impact factor: 2.646

10.  Tuberculosis Screening, Testing, and Treatment of U.S. Health Care Personnel: Recommendations from the National Tuberculosis Controllers Association and CDC, 2019.

Authors:  Lynn E Sosa; Gibril J Njie; Mark N Lobato; Sapna Bamrah Morris; William Buchta; Megan L Casey; Neela D Goswami; MaryAnn Gruden; Bobbi Jo Hurst; Amera R Khan; David T Kuhar; David M Lewinsohn; Trini A Mathew; Gerald H Mazurek; Randall Reves; Lisa Paulos; Wendy Thanassi; Lorna Will; Robert Belknap
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2019-05-17       Impact factor: 17.586

View more
  2 in total

1.  Is the New Interferon-Gamma Releasing Assay Beneficial for the Diagnosis of Latent and Active Mycobacterium tuberculosis Infections in Tertiary Care Setting?

Authors:  Jaewan Jung; Byung Woo Jhun; Mijeong Jeong; Sun Joo Yoon; Hee Jae Huh; Chul Won Jung; Kihyun Kim; Jae Berm Park; Dae Joong Kim; Wooseong Huh; Hye Ryoun Jang; Young-Ho Kim; Sung Noh Hong; Doo Ryeon Chung; Eun-Suk Kang
Journal:  J Clin Med       Date:  2021-03-29       Impact factor: 4.241

2.  The Relationship between Pre-Pandemic Interferon Gamma Release Assay Test Results and COVID-19 Infection: Potential Prognostic Value of Indeterminate IFN-γ Release Assay Results.

Authors:  Sermin Borekci; Fatma Gulsum Karakas; Serhat Sirekbasan; Bahar Kubat; Rıdvan Karaali; Gunay Can; Bekir Sami Kocazeybek; Bilun Gemicioglu
Journal:  Can J Infect Dis Med Microbiol       Date:  2021-07-31       Impact factor: 2.471

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.